Developer docs
API playgroundTry for free, no card

Search company profiles

Quark Pharmaceuticals

Full company profile

uuid0008h66

Namestring
Quark Pharmaceuticals
Websiteurl
quarkpharma.com
Company typeenum
Private
Founded yearint
1994
Descriptiontext

Quark Pharmaceuticals is a private, clinical-stage pharmaceutical company headquartered in Fremont, California, founded in 1994 and operating with an estimated 51–100 employees. The company is engaged in the discovery and development of novel RNAi-based therapeutics, with a stated core technology of siRNA (small interfering RNA) gene silencing.

The company has historically pursued capital through a series of equity funding rounds between 2001 and 2010, raising an identified cumulative total of approximately $61 million from investors including SBI Asset Management and Tako Ventures. There is no public documentation of commercialized products, named clinical partners, licensing deals, or regulatory milestones beyond what is implicit in a clinical-stage RNAi platform company. Leadership consists of founder and chair-CEO Daniel Zurr, CSO Elena Feinstein, COO Rami Skaliter, and President of US Operations / CMO Shai Erlich.

The available data does not include revenue, pricing, customer segments, product pipeline details, intellectual property portfolio, or post-2010 operating activity. The company's public website (quarkpharma.com) currently displays a cPanel default error page rather than active content, and no current operating status is independently verifiable from the source materials.

Short descriptiontext

Quark Pharmaceuticals is a private, clinical-stage biopharmaceutical company founded in 1994 and based in Fremont, California, developing novel RNAi-based therapeutics built on siRNA gene-silencing technology, with no disclosed commercial products in the available data.

Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersFremont, United States
HQ citystring
Fremont
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
RNAi-based therapeutics, siRNA gene silencing, clinical-stage pharmaceuticals, novel drug discovery, RNA-based drug development
Industry4 codes
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
RNAi-based Biopharmaceuticals
Social media profiles1 record
Cost components3 values
Personnel, Technology or R&D, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics. The company applies siRNA (small interfering RNA) gene silencing technology to develop innovative drug candidates targeting serious disease indications. As a clinical-stage company, its focus is on advancing therapeutic candidates through preclinical and clinical development rather than commercial product sales.

Differentiator
Functional benefit
Problem solved
Recent move4 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Alnylam is the leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, Oxlumo, Amvuttra). It is the reference incumbent in Quark's exact modality and target indications (genetic disease gene silencing) and the dominant benchmark for any siRNA clinical asset value.

TypeDirect peer
Description

Arrowhead is a clinical-stage siRNA therapeutics company with a broad pipeline and proprietary delivery technology (TRiM). It competes head-to-head for the same RNAi partnerships and licensing deals that Quark would pursue, making it the most direct comparable peer.

TypeDirect peer
Description

Silence Therapeutics is a clinical-stage siRNA company (mRNA and gene silencing) with its own GalNAc delivery platform and a notable partnership with AstraZeneca. It is a direct peer in modality, stage, and go-to-market via big-pharma licensing.

TypeDirect peer
Description

Wave is an oligonucleotide therapeutics company focused on gene silencing using stereopure chemistries (PRISM platform), directly comparable to Quark's siRNA chemistry focus and clinical-stage positioning.

TypeBroad incumbent
Description

Ionis is a leading RNA-targeted therapeutics company with multiple approved antisense drugs (Spinraza, Tegsedi, Waylivra) and broad partnerships. It operates in the adjacent RNA therapeutics space that overlaps with siRNA gene silencing and is a frequent counterpart in licensing deals.

TypeDirect peer
Description

Dicerna was a clinical-stage siRNA company (GalXC platform) acquired by Novo Nordisk in 2021 for $3.3B. Its pre-acquisition trajectory (clinical-stage RNAi, partnership-driven, similar headcount to Quark at acquisition) makes it the most relevant precedent transaction comp.

TypeDirect peer
Description

Sirnaomics is a clinical-stage RNAi therapeutics company with both siRNA and mRNA programs, including oncology and anti-fibrotic indications. It is comparable in modality, clinical stage, and platform breadth to Quark's stated focus.

TypeDirect peer
Description

Sylentis is a clinical-stage siRNA therapeutics subsidiary of Pharma Mar focused on ophthalmology and other indications. It is comparable as a niche clinical-stage siRNA player with a small focused pipeline targeting similar delivery and indication profiles.

TypeBroad incumbent
Description

Arcturus is a clinical-stage RNA therapeutics company developing mRNA, siRNA, and related platforms including a partnered COVID vaccine. Its broader RNA platform approach and clinical-stage status make it a relevant adjacent peer for RNA modality comparison.

TypeEmerging player
Description

Noxxon is a clinical-stage company developing Spiegelmer-based oligonucleotide therapeutics that intercept disease-related proteins. It is comparable as a small clinical-stage oligonucleotide therapeutics company pursuing gene-expression modulation via RNA-based mechanisms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat2 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Quark Pharmaceuticals

RNAi-based Biopharmaceuticalsquarkpharma.com

Quark Pharmaceuticals is a private, clinical-stage biopharmaceutical company founded in 1994 and based in Fremont, California, developing novel RNAi-based therapeutics built on siRNA gene-silencing technology, with no disclosed commercial products in the available data.

What Quark Pharmaceuticals does

Quark Pharmaceuticals is a private, clinical-stage pharmaceutical company headquartered in Fremont, California, founded in 1994 and operating with an estimated 51–100 employees. The company is engaged in the discovery and development of novel RNAi-based therapeutics, with a stated core technology of siRNA (small interfering RNA) gene silencing.

The company has historically pursued capital through a series of equity funding rounds between 2001 and 2010, raising an identified cumulative total of approximately $61 million from investors including SBI Asset Management and Tako Ventures. There is no public documentation of commercialized products, named clinical partners, licensing deals, or regulatory milestones beyond what is implicit in a clinical-stage RNAi platform company. Leadership consists of founder and chair-CEO Daniel Zurr, CSO Elena Feinstein, COO Rami Skaliter, and President of US Operations / CMO Shai Erlich.

The available data does not include revenue, pricing, customer segments, product pipeline details, intellectual property portfolio, or post-2010 operating activity. The company's public website (quarkpharma.com) currently displays a cPanel default error page rather than active content, and no current operating status is independently verifiable from the source materials.

Quark Pharmaceuticals firmographics

Firmographics
Name
Quark Pharmaceuticals
Website
https://quarkpharma.com
Company type
Private
Founded year
1994
Headcount range
11–50 employees
Short description
Quark Pharmaceuticals is a private, clinical-stage biopharmaceutical company founded in 1994 and based in Fremont, California, developing novel RNAi-based therapeutics built on siRNA gene-silencing technology, with no disclosed commercial products in the available data.
Ownership category
akta.pro rank

Quark Pharmaceuticals industry classification

Industry
Product category
RNAi-based Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAADAB
siRNA Therapeutics (gene silencing)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAH
RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAE
RNA Chemistry & Oligonucleotide Engineering (backbones, modifications, stereochemistry)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)
SECONDARYHLAAADAG
RNA Therapeutics Platforms & Design (sequence design, target ID/validation, AI/bioinformatics)
Healthcare & Life Sciences/Biotechnology & Biologics/RNA Therapeutics (mRNA, siRNA, ASO)

Keywords

  • RNAi-based therapeutics
  • SiRNA gene silencing
  • Clinical-stage pharmaceuticals
  • Novel drug discovery
  • RNA-based drug development

Where Quark Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Fremont
HQ country
United States
HQ region
North America

Markets served

Quark Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations

Quark Pharmaceuticals product offering

Product offering

Core offering

Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics. The company applies siRNA (small interfering RNA) gene silencing technology to develop innovative drug candidates targeting serious disease indications. As a clinical-stage company, its focus is on advancing therapeutic candidates through preclinical and clinical development rather than commercial product sales.

Differentiator

Problem solved

Functional benefit

Companies that use Quark Pharmaceuticals

Customer profile

Ideal customer profiles2 records

Quark Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Quark Pharmaceuticals partnerships and signals

Strategic signal

Recent moves4 records

Expansion highlights2 records

Quark Pharmaceuticals competitors and assessment

Company assessment

Broad incumbents

  • Alnylam Pharmaceuticals: Alnylam is the leading commercial-stage siRNA therapeutics company (Onpattro, Givlaari, Oxlumo, Amvuttra). It is the reference incumbent in Quark's exact modality and target indications (genetic disease gene silencing) and the dominant benchmark for any siRNA clinical asset value.
  • Ionis Pharmaceuticals: Ionis is a leading RNA-targeted therapeutics company with multiple approved antisense drugs (Spinraza, Tegsedi, Waylivra) and broad partnerships. It operates in the adjacent RNA therapeutics space that overlaps with siRNA gene silencing and is a frequent counterpart in licensing deals.
  • Arcturus Therapeutics: Arcturus is a clinical-stage RNA therapeutics company developing mRNA, siRNA, and related platforms including a partnered COVID vaccine. Its broader RNA platform approach and clinical-stage status make it a relevant adjacent peer for RNA modality comparison.

Direct peers

  • Arrowhead Pharmaceuticals: Arrowhead is a clinical-stage siRNA therapeutics company with a broad pipeline and proprietary delivery technology (TRiM). It competes head-to-head for the same RNAi partnerships and licensing deals that Quark would pursue, making it the most direct comparable peer.
  • Silence Therapeutics: Silence Therapeutics is a clinical-stage siRNA company (mRNA and gene silencing) with its own GalNAc delivery platform and a notable partnership with AstraZeneca. It is a direct peer in modality, stage, and go-to-market via big-pharma licensing.
  • Wave Life Sciences: Wave is an oligonucleotide therapeutics company focused on gene silencing using stereopure chemistries (PRISM platform), directly comparable to Quark's siRNA chemistry focus and clinical-stage positioning.
  • Dicerna Pharmaceuticals: Dicerna was a clinical-stage siRNA company (GalXC platform) acquired by Novo Nordisk in 2021 for $3.3B. Its pre-acquisition trajectory (clinical-stage RNAi, partnership-driven, similar headcount to Quark at acquisition) makes it the most relevant precedent transaction comp.
  • Sirnaomics: Sirnaomics is a clinical-stage RNAi therapeutics company with both siRNA and mRNA programs, including oncology and anti-fibrotic indications. It is comparable in modality, clinical stage, and platform breadth to Quark's stated focus.
  • Sylentis (Pharma Mar): Sylentis is a clinical-stage siRNA therapeutics subsidiary of Pharma Mar focused on ophthalmology and other indications. It is comparable as a niche clinical-stage siRNA player with a small focused pipeline targeting similar delivery and indication profiles.

Emerging players

  • Noxxon Pharma: Noxxon is a clinical-stage company developing Spiegelmer-based oligonucleotide therapeutics that intercept disease-related proteins. It is comparable as a small clinical-stage oligonucleotide therapeutics company pursuing gene-expression modulation via RNA-based mechanisms.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

Quark Pharmaceuticals social profiles

Digital presence

Quark Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Quark Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles4 records

Quark Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Quark Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Quark Pharmaceuticals

What does Quark Pharmaceuticals do?

Quark Pharmaceuticals is a clinical-stage pharmaceutical company engaged in the discovery and development of novel RNAi-based therapeutics. The company applies siRNA (small interfering RNA) gene silencing technology to develop innovative drug candidates targeting serious disease indications. As a clinical-stage company, its focus is on advancing therapeutic candidates through preclinical and clinical development rather than commercial product sales.

Is Quark Pharmaceuticals a public or private company?

Quark Pharmaceuticals is a private company. It is classified as venture growth investor backed.

When was Quark Pharmaceuticals founded?

Quark Pharmaceuticals was founded in 1994. It employs 11 to 50 people.

Where is Quark Pharmaceuticals based?

Quark Pharmaceuticals is headquartered in Fremont, United States, in the North America region.

Who are Quark Pharmaceuticals's main competitors?

Broad incumbents on record are Alnylam Pharmaceuticals, Ionis Pharmaceuticals and Arcturus Therapeutics. Direct peers are Arrowhead Pharmaceuticals, Silence Therapeutics, Wave Life Sciences, Dicerna Pharmaceuticals, Sirnaomics and Sylentis (Pharma Mar). Noxxon Pharma is listed as an emerging player.

Does Quark Pharmaceuticals have an API?

No public API is recorded for Quark Pharmaceuticals.

What industry is Quark Pharmaceuticals in?

Quark Pharmaceuticals's product category is RNAi-based Biopharmaceuticals. Its primary akta.pro industry code is HLAAADAB, siRNA Therapeutics (gene silencing), with a secondary code of HLAAADAH, RNA Therapeutics Clinical Development (trial design, endpoints, patient stratification). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireGlobal RNA-interference (RNAi) Market Growth, Trends and Forecasts to 2025: Focus on Key Players Alnylam Pharmaceuticals, Arrowhead, Quark Pharmaceuticals Inc. and Qiagen NVAccording to market research published by ResearchAndMarkets.com, the global RNA-interference (RNAi) market is projected to grow at a compound annual growth rate of 10.12% during the forecast period of 2020-2025, driven by increasing applications in molecular diagnostics for cancer and improvements in synthetic delivery carriers and RNA chemical modifications. The oncology segment is expected to hold significant market share as advancements in siRNA development and non-viral vectors facilitate clinical use of RNAi-based cancer therapeutics. However, the market faces a restraint from stringent FDA regulations and declining drug approval rates, which could impede growth particularly for newer genetic medicine approaches like miRNAs and siRNAs that require intensive clinical trials.PR NewswireGlobal RNA Interference (RNAi) IndustryThe global RNA Interference (RNAi) market is projected to grow by US$39.9 billion at a compound annual growth rate of 18.5%, with the Drug Discovery & Development segment expected to reach over US$23.3 billion by 2025. China is forecast to exhibit the strongest growth at 21.6%, adding approximately US$8.6 billion in addressable opportunity, while the United States will maintain a 17.1% growth momentum and Germany will contribute over US$1.8 billion in Europe. The report identifies Alnylam Pharmaceuticals, Benitec BioPharma, Ionis Pharmaceuticals, Qiagen, Quark Pharmaceuticals, and Silence Therapeutics as key competitors in this space.PR NewswireRNAi Technologies Market 2019, Industry Analysis, Competitors Strategy, Trends and Demands, Key Applications, Forecast To 2025This market research report analyzes the global RNAi (Ribonucleic Acid Interference) Technologies market, covering key companies including Alnylam Pharmaceuticals, Benitec Biopharma, Ionis Pharmaceuticals, Quark Pharmaceuticals, and Qiagen among others. The report examines market size, production, consumption, market share, growth rate, and forecasts from 2019 to 2025, with application segments including oncology, ocular disorders, respiratory disorders, and liver diseases for both research and therapeutic uses. The RNAi technology is described as a promising replacement for recombinant technology in drug discovery and therapeutics.GlobeNewswireQuark Pharmaceuticals, Inc. Announces First Patient Dosed in Phase 3 Clinical Trial of QPI-1002 for Prevention of Acute Kidney Injury Following Cardiac SurgeryQuark Pharmaceuticals announced the first patient dosed in its Phase 3 trial of QPI-1002, a siRNA targeting p53, to prevent acute kidney injury after cardiac surgery. The double-blind, placebo-controlled study will enroll about 1,038 high-risk patients at 115 sites globally, with the primary endpoint being Major Adverse Kidney Events at Day 90. The company expects first interpretative results in the fourth quarter of 2018.PR NewswireAcute Kidney Injury Therapeutics Pipeline 2018: Witnessing Strong Growth due to Increasing Research FundingResearchAndMarkets.com published a 2018 market report analyzing the Acute Kidney Injury (AKI) therapeutics pipeline, identifying approximately 40 drug candidates in various development stages with most administered intravenously for higher bioavailability. The report notes increasing research funding from organizations like the National Institute of Diabetes and Digestive and Kidney Diseases and the SBA's SBIR program, alongside growing patent approvals for AKI drug candidates. Key players identified include Quark Pharmaceuticals, Silver Creek Pharmaceuticals, Stealth BioTherapeutics, Angion Biomedica, Alloksys Life Sciences, Arch BioPartners, and TheraSource.PR NewswireQuark Pharmaceuticals, Inc. to Present Preclinical Efficacy Data on Inhaled siRNA Co-Developed with Biocon for Prevention of Primary Graft Dysfunction following Lung Transplantation at the 6th AnnualQuark Pharmaceuticals and Biocon announced that preclinical data for an inhaled siRNA therapy developed to prevent primary graft dysfunction after lung transplantation will be presented at the 6th Annual RNAi China Conference. The asset was co-developed by Quark's scientific team and researchers from Washington University School of Medicine, with collaboration from Biocon scientists under a licensing agreement. This presentation highlights the progress of the therapeutic candidate toward clinical development phases.PR NewswireQuark Pharmaceuticals RNAi Drug Succeeds in Phase 2 Study to Prevent Acute Kidney Injury Following Cardiac SurgeryQuark Pharmaceuticals announced successful completion of a randomized, double-blinded, placebo-controlled multicenter Phase 2 trial of QPI-1002, an RNAi drug, for prophylaxis of acute kidney injury following cardiac surgery in 341 subjects aged 45 or greater. The study met its primary endpoint with statistically significant reduction in AKI incidence through Day 5, with consistent treatment effects across predefined subgroups including patients with chronic kidney disease, diabetes, and high-risk patients undergoing multiple cardiovascular procedures. The drug appeared well tolerated and supports continued development, with a Phase 3 clinical study already underway for reduction of delayed graft function incidence and severity.PR NewswireQuark Pharmaceuticals Inc - Product Pipeline Review - 2016Quark Pharmaceuticals Inc's product pipeline is reviewed, providing insights into its pharmaceutical research and development activities. The report covers various stages of drug development and includes extensive information about drug targets, mechanisms of action, and a comparative analysis of nearly 3,000 indications. It aims to assist in strategic decision-making and competitive positioning in the pharmaceutical market.PR NewswireRibonucleic Acid Interference (RNAi) Technology Market: By Application (Research and Development, Therapeutics, Drug Discovery, Agriculture), By Tools (Design/Software, Delivery Based, Monitoring, LibThis report provides an overview of the global RNAi (Ribonucleic Acid Interference) technology market, covering the period 2014-2021, and segments it by application (Research and Development, Therapeutics, Drug Discovery, Agriculture), tools (Design/Software, Delivery Based, Monitoring, Libraries), and region. North America dominated the market due to its large pharmaceutical industry investing heavily in R&D, while Asia Pacific is projected to experience the fastest growth driven by expanding pharmaceutical infrastructure and government initiatives in developing nations. The report identifies key players in the RNAi technology market including F. Hoffmann-La Roche AG, Alnylam Pharmaceuticals, Arrowhead Research Corporation, Quark Pharmaceuticals Inc., and RXi Pharmaceuticals Corp.PR NewswireRNAi Therapeutics Market, 2015 - 2030The RNAi therapeutics market is forecast to reach $18.6 billion by 2030, with at least 11 therapies expected to be commercially available. The market is led by start-ups, with 180 products in development, 20% in clinical phases. Investment since 2013 has totaled $2.2 billion.